Abstract | PURPOSE: EXPERIMENTAL DESIGN: In this phase 2, open-label study, the efficacy of dasatinib (140 mg/d) was investigated in 67 patients with various Ph- myeloid disorders, including SM (n = 33; 28 KIT-D816V positive). RESULTS: CONCLUSION: These data show that dasatinib therapy may benefit a selected group of SM patients, primarily by improving their symptoms, but it does not eliminate the disease in the patients with KIT-D816V mutation.
|
Authors | Srdan Verstovsek, Ayalew Tefferi, Jorge Cortes, Susan O'Brien, Guillermo Garcia-Manero, Animesh Pardanani, Cem Akin, Stefan Faderl, Taghi Manshouri, Deborah Thomas, Hagop Kantarjian |
Journal | Clinical cancer research : an official journal of the American Association for Cancer Research
(Clin Cancer Res)
Vol. 14
Issue 12
Pg. 3906-15
(Jun 15 2008)
ISSN: 1078-0432 [Print] United States |
PMID | 18559612
(Publication Type: Clinical Trial, Phase II, Journal Article)
|
Chemical References |
- Antineoplastic Agents
- Pyrimidines
- Thiazoles
- Dasatinib
|
Topics |
- Adult
- Aged
- Antineoplastic Agents
(adverse effects, therapeutic use)
- Dasatinib
- Female
- Humans
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
(drug therapy)
- Leukemia, Myeloid, Acute
(drug therapy)
- Male
- Mastocytosis, Systemic
(drug therapy)
- Middle Aged
- Philadelphia Chromosome
- Pyrimidines
(adverse effects, therapeutic use)
- Remission Induction
- Thiazoles
(adverse effects, therapeutic use)
- Treatment Outcome
|